脑脊液生物标志物纵向变化率与早期Braak分期tau PET负荷的关联
本研究回顾性分析120例认知正常个体,发现脑脊液p-tau181和t-tau水平较高及其既往上升速率较快,与随后Braak I-II期亚区tau PET负荷较高显著相关;而Aβ42/Aβ40变化速率与后续tau负荷无关。
要点
- 脑脊液p-tau181和t-tau基线水平及上升速率与早期Braak分期tau PET负荷正相关。
- Aβ42/Aβ40基线水平较低与后续tau负荷相关,但其纵向变化速率无显著关联。
- tau PET仅单时间点采集,限制了对PET与脑脊液标志物时序关系的推断。
核心结论
- 脑脊液tau和p-tau随时间的升高与Braak I-II期亚区tau PET负荷增加相关。
研究设计与样本
- 回顾性分析认知正常个体队列(NIH与约翰霍普金斯大学),共120人,基线年龄32-78岁,平均57岁,女性60%。
- 78人提供纵向脑脊液数据(424次观测),平均在tau PET采集前12.8年每两年采集一次;另42人仅提供基线脑脊液用于横断面分析。
主要发现
- 脑脊液p-tau181较高与Braak I和II期tau PET负荷较高相关(β=0.567 [0.411-0.724];β=0.508 [0.344-0.671])。
- 脑脊液t-tau较高与Braak I和II期tau PET负荷较高相关(β=0.411 [0.260-0.562];β=0.393 [0.240-0.547])。
- p-tau181既往上升速率较快与Braak I和II期tau PET负荷较高相关(β=0.016 [0.008-0.024];β=0.018 [0.011-0.025])。
- t-tau既往上升速率较快与Braak I和II期tau PET负荷较高相关(β=0.015 [0.009-0.022];β=0.016 [0.010-0.022])。
- Aβ42/Aβ40较低与后续tau负荷相关(β=-0.556 [-0.706至-0.406];β=-0.503 [-0.653至-0.353]),但其变化速率无显著关联。
临床怎么用
- 在认知正常个体中,动态监测脑脊液p-tau181和t-tau的上升速率可能有助于提示早期Braak I-II期tau沉积风险。
局限性
- tau PET仅在单一时间点采集,限制了对PET与脑脊液标志物时序演变的推断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Changes in CSF and tau PET biomarkers of Alzheimer disease (AD) emerge years before clinical symptoms are observed. However, few studies have examined the temporal relationship between these measures. This study investigated whether longitudinal changes in CSF AD biomarkers were associated with 18F-MK6240 tau PET measures in early Braak stage subregions. METHODS: This study involved a retrospective analysis of cognitively unimpaired participants from the longitudinal observational Biomarkers of Cognitive Decline Among Normal Individuals cohort (NIH and Johns Hopkins University). Phosphorylated tau (p-tau) 181, total tau (t-tau), and β-amyloid (Aβ)42/Aβ40) measures were obtained from CSF collected biennially over a mean of 12.8 years before tau PET acquisition. Linear mixed-effect models examined how previous CSF biomarker levels and rates of change in these measures related to subsequent tau deposition corresponding to Braak stages I and II. RESULTS: A total of 120 cognitively unimpaired individuals (baseline age range 32-78 years; mean age 57 years; 60% female) were included in the analysis, including 78 participants with longitudinal CSF data (424 observations) and 42 additional participants contributing to cross-sectional analyses of initial CSF levels only. Results showed that higher levels of CSF p-tau181 (β = 0.567 [0.411-0.724]; β = 0.508 [0.344-0.671]) and t-tau (β = 0.411 [0.260-0.562]; β = 0.393 [0.240-0.547]), as well as steeper previous rates of increase in p-tau181 (β = 0.016 [0.008-0.024]; β = 0.018 [0.011-0.025]) and t-tau (β = 0.015 [0.009-0.022]; β = 0.016 [0.010-0.022]), were significantly associated with subsequent higher tau PET burden in Braak stages I and II. By contrast, although lower Aβ42/Aβ40 levels were associated with subsequent tau burden (β = -0.556 [-0.706 to -0.406]; β = -0.503 [-0.653 to -0.353]), the rate of change in Aβ42/Aβ40 over time was not. DISCUSSION: These findings show that tau PET burden in Braak stage I and II subregions is associated with increases in CSF tau and p-tau over time, offering important insights into the relationships among key biomarkers for the diagnosis and staging of AD, although tau PET was collected at only a single time point, limiting inferences about the temporal evolution of PET-CSF relationships.
引用
- Rani N, Moghekar A, Callow DD, et al. Association Between Longitudinal Rate of Change in CSF Biomarkers and Subsequent Tau PET Burden in Early Braak Stages. Neurology. 2026. PMID: 41604611. doi:10.1212/WNL.0000000000214620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。